(E/Z)-GSK5182

TargetMol
Product Code: TAR-T7709
Supplier: TargetMol
CodeSizePrice
TAR-T7709-1mg1mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7709-5mg5mg£332.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7709-1mL1 mL * 10 mM (in DMSO)£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7709-10mg10mg£458.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7709-25mg25mg£703.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7709-50mg50mg£938.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7709-100mg100mg£1,267.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
(E/Z)-GSK5182 is a racemic compound of (E)-GSK5182 and (Z)-GSK5182 isomers. GSK5182 is a highly selective and orally active estrogen-related receptor γ (ERRγ) inverse agonist(IC50 of 79 nM),and also induces reactive oxyen species (ROS) generation in hepatocellular carcinoma
CAS:
T7709
Formula:
C27H31NO3
Molecular Weight:
417.54
Pathway:
Immunology/Inflammation; Endocrinology/Hormones
Purity:
0.9883
SMILES:
CN(C)CCOC1=CC=C(C=C1)C(=C(CCCO)C1=CC=CC=C1)C1=CC=C(O)C=C1
Target:
Estrogen/progestogen Receptor; ROS

References

Misra J, et al. ERR?: a Junior Orphan with a Senior Role in Metabolism. Trends Endocrinol Metab. 2017 Apr;28(4):261-272. Kim DK, et al. Inverse agonist of nuclear receptor ERR? mediates antidiabetic effect through inhibition of hepatic gluconeogenesis. Diabetes. 2013 Sep;62(9):3093-102. Kim JH, et al. Estrogen-related receptor ? is upregulated in liver cancer and its inhibition suppresses livercancer cell proliferation via induction of p21 and p27. Exp Mol Med. 2016 Mar 4;48:e213.